
Vaccine Supply Dispute Between EU and AstraZeneca Continues
The dispute between the European Commission (EC) of the European Union and pharmaceutical company AstraZeneca continues.
The dispute between the European Commission (EC) of the European Union and pharmaceutical company AstraZeneca continues, as the head of the EC, Ursula von der Leyen, calls on AstraZeneca for the publication of the confidential vaccine contract on Friday Jan. 29, 2021.
According to multiple news sources, von der Leyen has specified, in a
Currently, AstraZeneca has revealed that it will only be able to supply a quarter of the originally agreed number of doses before the end of March as a result of the production problems being faced at the European plants. However, EU Health Commissioner, Stella Kyriakides, has insisted that the company utilize production facilities in the United Kingdom to help meet their contractual obligement for doses to the EU.
Pascal Soriot, CEO of AstraZeneca, has been quoted in
In
At the time of writing, the AstraZeneca/Oxford vaccine has not received regulatory approval in Europe.
Sources:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.